Companies in #Diabetes
Found 5 companies operating in this sector.
Curanex Pharmaceuticals is a developmental-stage pharmaceutical company discovering, developing, and commercializing botanical drugs for inflammatory and other serious diseases. Its lead candidate, Phyto-N, is being advanced across ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with a 2026 pipeline expansion into cancer cachexia and advanced cancer supportive care. The company completed GMP manufacturing and toxicology milestones supporting a planned Q4 2026 IND submission for ulcerative colitis. Curanex (formerly Fordman Pharma, renamed November 2023) listed on Nasdaq in August 2025 at $4.00 per share and implemented a 1-for-20 reverse stock split effective August 20, 2026 to maintain listing compliance, reducing shares outstanding to approximately 1.57 million.
Insulet Corporation is a medical device company best known for its Omnipod insulin management system, the only tubeless insulin pump available in the U.S. Insulet is expanding into adjacent chronic disease management through technology partnerships.
Mitsubishi Tanabe Pharma is a Japanese pharmaceutical company with a portfolio spanning immunology, central nervous system disorders, diabetes, and vaccines. It is the originator of Radicava (edaravone) for ALS and has been divesting non-core plants as part of a post-buyout strategic pivot.
Novo Nordisk is a Danish multinational pharmaceutical company that discovers, develops, and markets therapies for diabetes, obesity, rare endocrine disorders, and other chronic diseases. The company is the world's largest insulin producer and a leading developer of GLP-1 receptor agonists for diabetes (Ozempic, Rybelsus) and obesity (Wegovy), with a deep pipeline in cardiometabolic and rare-disease therapeutics.
Sanofi (NASDAQ: SNY; Euronext: SAN) is a global biopharmaceutical company with major franchises in immunology (Dupixent, partnered with Regeneron), vaccines (Beyfortus, Fluzone, Dengvaxia), rare disease (Genzyme-legacy Pompe, Fabry, MS), and a growing oncology pipeline. Sanofi has been reshaping its R&D portfolio toward immunology and rare disease while spinning off its consumer health unit.